AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04679675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in
Description: Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
Study NCT03680638 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (Lactated Ringer's)
Description: This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
Study NCT03680638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tempol
Description: This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
Study NCT03806140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messages
Description: receive about one health-related text message a day for 16 weeks
Study NCT00439244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
Study NCT00439244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
Study NCT00439244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
Study NCT00439244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days.
Study NCT01018251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: Given IV
Study NCT01018251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/computed tomography
Study NCT01018251 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT-PET/CT
Study NCT03731169 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Voriconazole genotype-specific dosing
Description: Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.
Study NCT03731169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
Study NCT00789659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Description: A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
Study NCT01331798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohera TissuGlu Surgical Adhesive
Description: TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
Study NCT01331798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control- Standard of care
Description: Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
Study NCT00488176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast sodium
Study NCT00488176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetirizine
Description: cetirizine
Study NCT00205374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cidofovir
Description: With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
Study NCT00205374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
Study NCT00488176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast and cetirizine
Description: montelukast and cetirizine
Study NCT00488176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02325375 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar puncture for spinal fluid and blood sample
Description: lumbar puncture for spinal fluid and blood sample
Study NCT01385553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change
Description: FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
Study NCT01385553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Drug Counseling
Description: Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
Study NCT03534557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FEV6 spirometry
Description: During the same spirometry, to compare the relative value of FVC and FEV6
Study NCT03057431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Once daily for 3 years
Study NCT03057431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide
Description: Once daily for 3 years
Study NCT03057431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25.0 mg hydrochlorothiazide
Description: Once daily for 3 years
Study NCT02665845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA
Description: 5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
Study NCT02665845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be given to all patients.
Study NCT02665845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids will be given to all patients.
Study NCT03996629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education and compliance
Description: When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
Study NCT01990482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffe
Study NCT01990482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffe
Study NCT01990482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Study NCT01990482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT02191761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: Escalating Doses
Study NCT03680638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
Study NCT03680638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
Study NCT00776750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent split influenza vaccine
Description: standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
Study NCT00763061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% Ophthalmic Solution (Travatan)
Description: Travoprost at 9 AM + Placebo \& 9 PM
Study NCT00763061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% Ophthalmic Solution (Timoptic)
Description: Timolol in each eye, twice daily at 9 AM \& 9 PM
Study NCT02024113 — intervention group
Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood
Study NCT01839318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lenses
Study NCT03783442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally
Study NCT03783442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV
Study NCT03783442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT03783442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered IV
Study NCT03783442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match Tislelizumab
Study NCT03393936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-38
Description: Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
Study NCT03393936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-59
Description: Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
Study NCT03057431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50.0 mg hydrochlorothiazide
Description: Once daily for 3 years
Study NCT04074460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anaesthesia
Study NCT04074460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane, sevoflurane or desflurane
Description: General Anaesthesia
Study NCT00203996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
Study NCT00203996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot leuprolide plus estrogen/progestin replacement
Description: Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
Study NCT00203996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
Study NCT00203996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REM frag
Description: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
Study NCT02209558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Sternal Precautions
Description: Visual depiction of SPs in addition to standard of care written precautions
Study NCT02265536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV
Study NCT03574766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Daily meditation
Study NCT00349349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Intravenous infusion
Study NCT00706108 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational study
Description: Observational (descriptive) study of technical and non-technical performance
Study NCT02566187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Atorvastatin Combination Tablet
Study NCT02566187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02566187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study NCT01925040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of restoration
Description: Placement of restorations
Study NCT01925040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of restoration
Description: Placement of restorations
Study NCT04645316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
Study NCT04645316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
Study NCT04645316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
Study NCT00144040 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician & patient education on appropriate antibiotic use
Study NCT00144040 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rapid C-reactive protein testing to guide antibiotic treatment
Study NCT03213145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraconazole
Description: Subjects will receive itraconazole once daily from Day 5 through Day18
Study NCT03213145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will receive rifampin once daily from Day 5 through Day 16
Study NCT03213145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Subjects will receive EDP 305 once daily on Day 1 and Day 14
Study NCT03380494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overhead perturbation training
Description: A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
Study NCT03380494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-perturbed training
Description: A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
Study NCT02973594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Study NCT02973594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03486769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal transcranial direct current stimulation